Kristina L. Bajema

Kristina L. Bajema

Auto-generated profile, based on publicly available information

Kristina L. Bajema

Centers for Disease Control and Prevention , Atlanta, Georgia , USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2020 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
KBKristina L. Bajema
Kristina L. Bajema
Health care providers should remain vigilant about possible 2019 novel coronavirus (2019-nCoV) exposures not only among returning travelers from China, but also among those in close contact with persons with 2019-nCoV in the United States.

10 December 2021 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
KBKristina L. Bajema
Kristina L. Bajema
Cynthia Ann Lucero-ObusanCynthia Ann Lucero-Obusan
Cynthia Ann Lucero-Obusan
This report describes vaccine effectiveness in preventing COVID-19-associated hospitalizations among U.S. veterans.

28 April 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
KBKristina L Bajema
Kristina L Bajema
RGRyan Gierke
Ryan Gierke
MFMonica M Farley
Monica M Farley
WSWilliam Schaffner
William Schaffner
ATAnn Thomas
Ann Thomas
TPTamara Pilishvili
Tamara Pilishvili
Background: Antibiotic-nonsusceptible invasive pneumococcal disease (NS-IPD) incidence declined dramatically in the United States after introduction of pneumococcal conjugate vaccines (PCVs) into the infant immunization schedule (7-valent PCV7 in 2000, replaced by the 13-valent PCV13 in 2010). We evaluated the long-term impact of PCVs on NS-IPD. Methods: We identified IPD cases through the Centers for Disease Control Active Bacterial Core surveillance during 1998–2018. Isolates intermediate or resistant to ≥1 antibiotic class were classified as nonsusceptible. We calculated annual rates of IPD (cases per 100 000 persons). Results: From 1998 through 2018, NS-IPD incidence decreased from 43.9 to 3.2 among children <5 years and from 19.8 to 9.4 among adults ≥65 years. Incidence of vaccine-type NS-IPD decreased in all age groups, whereas incidence of nonvaccine type (NVT) NS-IPD increased in all age groups; the greatest absolute increase in NVT NS-IPD occurred among adults ≥65 years (2.3 to 7.2). During 2014–2018, NVTs 35B, 33F, 22F, and 15A were the most common NS-IPD serotypes. Conclusions: Nonsusceptible IPD incidence decreased after PCV7 and PCV13 introduction in the United States. However, recent increases in NVT NS-IPD, most pronounced among older adults, have been observed. New higher valency PCVs containing the most common nonsusceptible serotypes, including 22F and 33F, could help further reduce NS-IPD.